130 related articles for article (PubMed ID: 12360152)
21. Overview of randomized clinical trials in acute heart failure syndromes.
Teerlink JR
Am J Cardiol; 2005 Sep; 96(6A):59G-67G. PubMed ID: 16181824
[TBL] [Abstract][Full Text] [Related]
22. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.
Cotter G; Kaluski E; Stangl K; Pacher R; Richter C; Milo-Cotter O; Perchenet L; Kobrin I; Kaplan S; Rainisio M; Frey A; Neuhart E; Vered Z; Dingemanse J; Torre-Amione G
Eur J Heart Fail; 2004 Aug; 6(5):601-9. PubMed ID: 15302008
[TBL] [Abstract][Full Text] [Related]
23. Effects of endothelin receptor antagonism on acute lung injury induced by chlorine gas.
Wang J; Oldner A; Winskog C; Edston E; Walther SM
Crit Care Med; 2006 Jun; 34(6):1731-7. PubMed ID: 16625121
[TBL] [Abstract][Full Text] [Related]
24. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
Qiu CB; Qiu CS; Hess P; Clozel JP; Clozel M
Acta Pharmacol Sin; 2001 Jun; 22(6):541-8. PubMed ID: 11747762
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.
Dingemanse J; Clozel M; van Giersbergen PL
Br J Clin Pharmacol; 2002 Apr; 53(4):355-62. PubMed ID: 11966665
[TBL] [Abstract][Full Text] [Related]
26. Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.
Cotter G; Kiowski W; Kaluski E; Kobrin I; Milovanov O; Marmor A; Jafari J; Reisin L; Krakover R; Vered Z; Caspi A
Eur J Heart Fail; 2001 Aug; 3(4):457-61. PubMed ID: 11511432
[TBL] [Abstract][Full Text] [Related]
27. Endothelin receptor blockade with tezosentan ameliorates myocardial injury induced by abdominal aortic ischemia-reperfusion.
Narin C; Kiris I; Gülmen S; Toy H; Yilmaz N; Sütcü R
Tohoku J Exp Med; 2008 Nov; 216(3):267-76. PubMed ID: 18987461
[TBL] [Abstract][Full Text] [Related]
28. Dual endothelin receptor blockade with tezosentan markedly attenuates hypoxia-induced pulmonary vasoconstriction in a porcine model.
Hedelin P; Kylhammar D; Rådegran G
Acta Physiol (Oxf); 2012 Mar; 204(3):419-34. PubMed ID: 21726419
[TBL] [Abstract][Full Text] [Related]
29. Haemodynamic and neuroendocrine effects of tezosentan in chronic experimental pulmonary hypertension.
Lourenço AP; Vasques-Nóvoa F; Oliveira-Pinto J; Fontoura D; Roncon-Albuquerque R; Leite-Moreira AF
Intensive Care Med; 2012 Jun; 38(6):1050-60. PubMed ID: 22349420
[TBL] [Abstract][Full Text] [Related]
30. Inhaled tezosentan reduces pulmonary hypertension in endotoxin-induced lung injury.
Persson BP; Rossi P; Weitzberg E; Oldner A
Shock; 2009 Oct; 32(4):427-34. PubMed ID: 19197226
[TBL] [Abstract][Full Text] [Related]
31. Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats.
Urbanowicz W; Sogni P; Moreau R; Tazi KA; Barriere E; Poirel O; Martin A; Guimont MC; Cazals-Hatem D; Lebrec D
Gut; 2004 Dec; 53(12):1844-9. PubMed ID: 15542526
[TBL] [Abstract][Full Text] [Related]
32. Pharmacology of new agents for acute heart failure syndromes.
Gheorghiade M; Teerlink JR; Mebazaa A
Am J Cardiol; 2005 Sep; 96(6A):68G-73G. PubMed ID: 16181825
[TBL] [Abstract][Full Text] [Related]
33. Acute cardiopulmonary effects of a dual-endothelin receptor antagonist on oleic acid-induced pulmonary arterial hypertension in dogs.
Wang L; Zhu DM; Su X; Bai CX; Ware LB; Matthay MA
Exp Lung Res; 2004; 30(1):31-42. PubMed ID: 14967602
[TBL] [Abstract][Full Text] [Related]
34. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome.
Wong F; Moore K; Dingemanse J; Jalan R
Hepatology; 2008 Jan; 47(1):160-8. PubMed ID: 17886336
[TBL] [Abstract][Full Text] [Related]
35. Tezosentan decreases pulmonary artery pressure and improves survival rate in an animal model of meconium aspiration.
Geiger R; Pajk W; Neu N; Maier S; Kleinsasser A; Fratz S; Navarro-Psiha S; Fischer V; Treml B; Loeckinger A
Pediatr Res; 2006 Jan; 59(1):147-50. PubMed ID: 16327003
[TBL] [Abstract][Full Text] [Related]
36. Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS).
Cleland JGF; Teerlink JR; Davison BA; Shoaib A; Metra M; Senger S; Milo O; Cotter G; Bourge RC; Parker JD; Jondeau G; Krum H; O'Connor CM; Torre-Amione G; van Veldhuisen DJ; McMurray JJV;
Eur J Heart Fail; 2017 Jun; 19(6):739-747. PubMed ID: 28296139
[TBL] [Abstract][Full Text] [Related]
37. Cardiopulmonary bypass is associated with altered vascular reactivity of isolated pulmonary artery in a porcine model: therapeutic potential of inhaled tezosentan.
Mommerot A; Denault AY; Dupuis J; Carrier M; Perrault LP
J Cardiothorac Vasc Anesth; 2014 Jun; 28(3):698-708. PubMed ID: 24917060
[TBL] [Abstract][Full Text] [Related]
38. Tezosentan. Actelion/Genentech.
Rossetti E; De Servi S
Curr Opin Investig Drugs; 2003 Mar; 4(3):323-8. PubMed ID: 12735233
[TBL] [Abstract][Full Text] [Related]
39. The development of new medical treatments for acute decompensated heart failure.
Teerlink JR
Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
[TBL] [Abstract][Full Text] [Related]
40. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets.
Chin A; Radhakrishnan J; Fornell L; John E
J Pediatr Surg; 2001 Dec; 36(12):1824-8. PubMed ID: 11733915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
